226
Views
2
CrossRef citations to date
0
Altmetric
Review

Varenicline for smoking cessation: a narrative review of efficacy, adverse effects, use in at-risk populations, and adherence

, &
Pages 435-441 | Published online: 01 Apr 2016

References

  • U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and HealthThe Health Consequences of Smoking – 50 Years of Progress: A Report of the Surgeon GeneralAtlanta, GAU.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health2014
  • JhaPPetoRGlobal effects of smoking, of quitting, and of taxing tobaccoN Engl J Med20143701606824382066
  • GohlkeHIs it worth offering cardiovascular disease prevention to the elderly?Eur J Prev Cardiol201320112112622089892
  • Cavazos-RehgPABreslauNHatsukamiDSmoking cessation is associated with lower rates of mood/anxiety and alcohol use disordersPsychol Med201444122523253525055171
  • DollRPetoRBorehamJSutherlandIMortality in relation to smoking: 50 years’ observations on male British doctorsBMJ20043287455151915213107
  • KenfieldSAStampferMJRosnerBAColditzGASmoking and smoking cessation in relation to mortality in womenJAMA2008299172037204718460664
  • NagrebetskyABrettellRRobertsNFarmerASmoking cessation in adults with diabetes: a systematic review and meta-analysis of data from randomised controlled trialsBMJ Open201443e004107
  • ThomsenTVillebroNMollerAMInterventions for preoperative smoking cessationCochrane Database Syst Rev20143CD00229424671929
  • FioreMTreating Tobacco Use and Dependence: 2008 Update: Clinical Practice GuidelineCollingdaleDIANE Publishing2008
  • SteadLFLancasterTBehavioural interventions as adjuncts to pharmacotherapy for smoking cessationCochrane Database Syst Rev201212CD00967023235680
  • SteadLFLancasterTCombined pharmacotherapy and behavioural interventions for smoking cessationCochrane Database Syst Rev201210CD00828623076944
  • CahillKStevensSPereraRLancasterTPharmacological interventions for smoking cessation: an overview and network meta-analysisCochrane Database Syst Rev20135CD00932923728690
  • SteadLFPereraRBullenCNicotine replacement therapy for smoking cessationCochrane Database Syst Rev201211CD00014623152200
  • KimYKornfieldRShiYEffects of televised direct-to-consumer advertising for varenicline on prescription dispensing in the United States, 2006–2009Nicotine Tob Res Epub2015918
  • HaysJTEbbertJOAdverse effects and tolerability of medications for the treatment of tobacco use and dependenceDrugs201070182357237221142259
  • ArnericSPHolladayMWilliamsMNeuronal nicotinic receptors: a perspective on two decades of drug discovery researchBiochem Pharmacol20077481092110117662959
  • SubramaniyanMDaniJADopaminergic and cholinergic learning mechanisms in nicotine addictionAnn N Y Acad Sci20151349466326301866
  • TapperARMcKinneySLNashmiRNicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitizationScience200430656981029103215528443
  • BenowitzNLNicotine addictionN Engl J Med2010362242295230320554984
  • EtterJFCytisine for smoking cessation: a literature review and a meta-analysisArch Intern Med2006166151553155916908787
  • CoeJWVetelinoMGBashoreCGIn pursuit of alpha4beta2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (−)-cytisineBioorg Med Chem Lett200515122974297915908213
  • HajekPMcRobbieHMyersKEfficacy of cytisine in helping smokers quit: systematic review and meta-analysisThorax201368111037104223404838
  • CahillKSteadLFLancasterTNicotine receptor partial agonists for smoking cessationCochrane Database Syst Rev20124CD00610322513936
  • MihalakKBCarrollFILuetjeCWVarenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptorsMol Pharmacol200670380180516766716
  • CoeJWBrooksPRVetelinoMGVarenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessationJ Med Chem200548103474347715887955
  • CohenCBergisOEGalliFSSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessationJ Pharmacol Exp Ther2003306140742012682217
  • RollemaHCoeJWChambersLKHurstRSStahlSMWilliamsKERationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessationTrends Pharmacol Sci200728731632517573127
  • FaesselHMSmithBJGibbsMAGobeyJSClarkDJBursteinAHSingle-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokersJ Clin Pharmacol200646999199816920893
  • ObachRSReed-HagenAEKruegerSSMetabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitroDrug Metab Dispos200634112113016221753
  • NiauraRHaysJTJorenbyDEThe efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trialCurr Med Res Opin20082471931194118513462
  • NidesMOnckenCGonzalesDSmoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-upArch Intern Med2006166151561156816908788
  • OnckenCGonzalesDNidesMEfficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessationArch Intern Med2006166151571157716908789
  • JorenbyDEHaysJTRigottiNAEfficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trialJAMA20062961566316820547
  • GonzalesDRennardSINidesMVarenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trialJAMA20062961475516820546
  • TonstadSTonnesenPHajekPWilliamsKEBillingCBReevesKREffect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trialJAMA20062961647116820548
  • TonstadSDaviesSFlammerMRussCHughesJPsychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysisDrug Saf201033428930120297861
  • Food and Drug AdministrationFDA drug safety communication: safety review update of Chantix (varenicline) and risk of neuropsychiatric adverse events Available from: http://www.fda.gov/Drugs/DrugSafety/ucm276737.htmAccessed August 2015
  • MeyerTETaylorLGXieSNeuropsychiatric events in varenicline and nicotine replacement patch users in the Military Health SystemAddiction2013108120321022812921
  • GibbonsRDMannJJVarenicline, smoking cessation, and neuropsychiatric adverse eventsAm J Psychiatry2013170121460146724030388
  • ThomasKHMartinRMKnipeDWHigginsJPGunnellDRisk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysisBMJ2015350h110925767129
  • Food and Drug AdministrationFDA Drug Safety Communication: Safety review update of Chantix (varenicline) and risk of cardiovascular adverse events Available from: http://www.fda.gov/Drugs/DrugSafety/ucm330367.htmAccessed August 2015
  • SinghSLokeYKSpanglerJGFurbergCDRisk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysisCMAJ2011183121359136621727225
  • HaysJTVarenicline for smoking cessation: is it a heartbreaker?CMAJ2011183121346134721727229
  • ProchaskaJJHiltonJFRisk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysisBMJ2012344e285622563098
  • MillsEJThorlundKEapenSWuPProchaskaJJCardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysisCirculation20141291284124323793
  • PachasGNCatherCPrattSAVarenicline for smoking cessation in schizophrenia: safety and effectiveness in a 12-week, open-label trialJ Dual Diagn20128211712522888309
  • EvinsAECatherCPrattSAMaintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trialJAMA2014311214515424399553
  • KoegelenbergCFNoorFBatemanEDEfficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trialJAMA2014312215516125005652
  • RamonJMMorchonSBaenaAMasuet-AumatellCCombining varenicline and nicotine patches: a randomized controlled trial study in smoking cessationBMC Med20141217225296623
  • EbbertJOHatsukamiDKCroghanITCombination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trialJAMA2014311215516324399554
  • EbbertJOHughesJRWestRJEffect of varenicline on smoking cessation through smoking reduction: a randomized clinical trialJAMA2015313768769425688780
  • CatzSLJackLMMcClureJBAdherence to varenicline in the COMPASS smoking cessation intervention trialNicotine Tob Res201113536136821350041
  • SuehsBTDavisCGalaznikAJoshiAVZouKHPatelNCAssociation of out-of-pocket pharmacy costs with adherence to vareniclineJ Manag Care Spec Pharm201420659260024856597
  • LibermanJNLichtenfeldMJGalaznikAAdherence to varenicline and associated smoking cessation in a community-based patient settingJ Manag Care Pharm201319212513123461428
  • HollandsGJMcDermottMSLindson-HawleyNVogtFFarleyAAveyardPInterventions to increase adherence to medications for tobacco dependenceCochrane Database Syst Rev20152CD00916425914910
  • NollenNLCoxLSNazirNA pilot clinical trial of varenicline for smoking cessation in black smokersNicotine Tob Res201113986887321498427